Figure 4.
Analysis based on the expression of progression signature among patients with stage I MF. (A) Patients with stage I MF with high-progression signature showed significantly increased CAF (P = .008), epithelial-mesenchymal transition (P = .025), JAK-STAT signaling (P = .059), NF-κB signaling (P < .001), and TCR signaling (P = .003) compared with those with low-progression signature. (B) Patients with stage I MF and a high-progression signature at diagnosis were more likely to progress (log-rank test, P < .001), receive radiation treatment (log-rank test, P = .023), and have a poor treatment response (P < .001) during follow-up than those with a low-progression signature. JAK-STAT, Janus kinase-signal transducer and activator of transcription; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCR, T-cell receptor.

Analysis based on the expression of progression signature among patients with stage I MF. (A) Patients with stage I MF with high-progression signature showed significantly increased CAF (P = .008), epithelial-mesenchymal transition (P = .025), JAK-STAT signaling (P = .059), NF-κB signaling (P < .001), and TCR signaling (P = .003) compared with those with low-progression signature. (B) Patients with stage I MF and a high-progression signature at diagnosis were more likely to progress (log-rank test, P < .001), receive radiation treatment (log-rank test, P = .023), and have a poor treatment response (P < .001) during follow-up than those with a low-progression signature. JAK-STAT, Janus kinase-signal transducer and activator of transcription; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCR, T-cell receptor.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal